* Juvisync is the first approved fixed-dose combination drug to treat type 2 diabetes and hyperlipidemia. It combines the anti-hyperglycemic drug sitagliptin (Januvia) with the antilipid drug simvastatin (Zocor).
* Various dose combinations will be available.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com.